supported by National Natural Science Foundation of China(81274122,81373997,U1402221,81573640,81273629);Beijing Natural Science Foundation(7131013);Specialized Research Fund for the Doctoral Program of Higher Education of China(20121106130001);Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study(BZ0150)
OBJECTIVE To evaluate these activities of Rg1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)/probenecid(MPTP/p)-induced PD mouse model for the first time and to elucidate the underlying mechanisms.METHODS M...
This work was supported by the National Natural Science Foundation of China (No 81274122, 81373997, 81273629, 81473376, U1402221, and 81573640), the National Mega-project for Innovative Drugs (No 2012ZX09301002-004), the Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) (No IRT1007), Beijing Natural Science Foundation (No 7131013 and 7161011), and the Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study (No BZ0150).
Aim: Accumulation of α-synuclein (a-syn) in the brain is a characteristic of Parkinson's disease (PD). In this study, we investigated whether treatment with tunicamycin, an endoplasmic reticulum (ER) stress i...